Gastrointestinal experimental models
Preclinical
Reviews summarize cytoprotective observations in gut-injury models. This is not an approved ulcer or IBD therapy.
Also known as Body Protection Compound-157, BPC 157, PL-10, stable gastric pentadecapeptide
Experimental pentadecapeptide investigated primarily in preclinical gastrointestinal and tissue-injury models. Human evidence is extremely limited.
BPC-157 is a synthetic 15–amino-acid peptide related to a sequence derived from human gastric juice proteins. A large preclinical literature describes effects in injury models. Independent reviews emphasize that human data are sparse and that the compound should be treated as investigational. It is not an FDA-approved medicine.
BPC-157 is a laboratory-made fragment (a pentadecapeptide) associated with gastric cytoprotection research.
Most published work is in animals or experimental systems. That is not the same as proven benefit in people.
It is widely discussed online. Popularity is not evidence of effectiveness or safety.
Researchers have proposed that BPC-157 may influence blood-vessel growth signals (including VEGF-related pathways) and nitric oxide signaling in injury models. Those ideas come mostly from animal work. They do not prove a medical treatment in humans.
Narrative reviews describe overlapping hypotheses including VEGFR2/Akt-eNOS signaling, ERK1/2 involvement, and modulation of nitric oxide pathways in cytoprotection models. These mechanistic stories are hypothesis-generating. Receptor identity as a classic drug target is not as clearly established as for approved receptor agonists such as GLP-1 medicines.
Step 1
Peptide
BPC-157 (synthetic pentadecapeptide)
Step 2
Proposed targets
Angiogenic and NO-related pathways hypothesized in preclinical papers
Step 3
Biological pathway
Cytoprotection / tissue-injury models in animals
Step 4
Observed research effect
Preclinical injury-model findings; human outcomes not established
Reviews summarize cytoprotective observations in gut-injury models. This is not an approved ulcer or IBD therapy.
A 2025 narrative review of musculoskeletal literature concluded that preclinical work is extensive but human data are extremely limited, and the peptide should remain investigational.
Review literature discusses experimental wound models. Clinical wound-care use is not established.
Reviews report only a handful of small human experiences (for example pilot contexts). These are insufficient to establish effectiveness or safety for routine use.
Extensive animal and experimental literature exists on gastrointestinal, tendon, and wound models. Quality, replication, and translational value vary and are not equivalent to clinical proof.
2007 · Review
Population: Mostly animal and experimental systems summarized by the authors
Objective: Review reported experimental effects of BPC 157 across organ-injury models.
Main finding: The review summarizes a wide range of preclinical observations. These summaries are not equivalent to proven clinical effectiveness in people.
Limitations: Narrative review of largely preclinical data; high risk of over-interpretation if treated as human outcome evidence.
2025 · Review
Population: Preclinical literature plus very limited human reports as described by the authors
Objective: Evaluate mechanisms, therapeutic potential, and safety concerns of BPC-157 in musculoskeletal contexts.
Main finding: The authors report extensive preclinical literature and extremely limited human data, and conclude the compound should be considered investigational until adequate clinical trials exist.
Limitations: Narrative/scoping methods; human evidence remains insufficient for routine care.
Safety information may be incomplete, especially for experimental peptides.
Safety information may be incomplete, especially for experimental peptides. Consult a qualified healthcare professional for personal medical advice.
Long-term safety: Not sufficiently established.
Evidence limitations: A large preclinical bibliography can coexist with almost no adequate clinical trials. Volume of animal papers is not proof of human benefit.
Administration practices vary by compound and clinical context. Follow approved prescribing information or guidance from a qualified healthcare professional. This page does not provide injection technique, mixing, or personalized dosing instructions. Routes described in experimental papers are not instructions for use.
Discovery
complete · 1990s
Described in gastric cytoprotection research programs.
Preclinical research
in progress
Large animal/cell literature continues.
Animal studies
in progress
Many organ-injury models reported.
Human studies
in progress
Very limited pilot-level human information according to reviews.
Clinical trials
not started
Adequate, well-controlled registrational trials for medical use are not established on this page.
Regulatory status
not started
Not an FDA-approved drug.
A synthetic 15–amino-acid peptide studied mainly in animals. It is not an approved medicine.
Preclinical papers explore gut, tendon, and wound-injury models. Those studies do not establish human treatments.
Proposed mechanisms involve angiogenic and nitric oxide-related signaling in experimental systems. The human mechanism, if any, is not sufficiently established.
Lots of animal data; extremely limited human data. Independent reviews call it investigational.
No. It is not FDA-approved for medical use.
Human safety is not adequately characterized. Unregulated product quality is an additional concern discussed in public-health literature.
Tissue Research
Marketed research peptide associated with thymosin beta-4 biology. Clinical effectiveness and product identity are not sufficiently established.
View peptide →